By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Cardiovascular Diseases are presented in a new report. According to news reporting originating from Frankfurt, Germany, by NewsRx editors, the research stated, "Lipid-lowering drug therapy with statins has become a cornerstone to reduce and prevent atherosclerosis and its detrimental complications like cardiovascular diseases and stroke. Due to the multifactorial pathogenesis of atherosclerosis the search for novel lipid-modifying drugs is still one of the most active areas in research and development in the pharmaceutical industry."
Our news editors obtained a quote from the research from Goethe-University, "Currently, the focus lies on novel LDL-cholesterol lowering drugs with a higher efficacy and improved safety profile as well as on approaches to increase plasma levels and functionality of high-density lipoproteins (HDL) based on the inverse relationship between high plasma HDL-levels and the risk for cardiovascular diseases. Whereas the today clinically used lipid-modifying drugs are predominantly small molecules for oral drug therapy a significant percentage of the drug candidates currently in development are biological drugs such as monoclonal antibodies and antisense oligonucleotides. Up-to-date around 70 novel drug molecules acting on about 20 different molecular targets are in clinical and preclinical development with antibodies inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) being the most intensively investigated and competitive approach. The clinical results reported so far with these antibodies are very promising whereas the clinical benefit for prevention of atherosclerosis and cardiovascular diseases by pharmacologically increasing of plasma high-density lipoproteins still remains to be demonstrated."
According to the news editors, the research concluded: "However, with the recent approval of 2 innovative drugs for the treatment of familial hypercholesterolemia and the promising clinical results of several novel drug candidates for LDL cholesterol lowering and high-density lipoprotein modulation one can expect the appearance of new drug breakthroughs for the treatment of dyslipidemia in the near future."
For more information on this research see: Novel Drug Approaches in Development for the Treatment of Lipid Disorders. Experimental and Clinical Endocrinology & Diabetes, 2013;121(10):567-580. Experimental and Clinical Endocrinology & Diabetes can be contacted at: Johann Ambrosius Barth Verlag Medizinverlage Heidelberg Gmbh, Ruedigerstr 14, D-70469 Stuttgart, Germany. (Thieme - www.thieme.com)
The news editors report that additional information may be obtained by contacting W. Kramer, Goethe Univ Frankfurt, Bioctr, Inst Biochem, Frankfurt, Germany (see also Cardiovascular Diseases).
Keywords for this news article include: Antibodies, Europe, Germany, Therapy, Frankfurt, Treatment, Cardiology, Immunology, Blood Proteins, Atherosclerosis, Immunoglobulins, Arteriosclerosis, Cardiovascular Diseases, Arterial Occlusive Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC